Psychiatry News

Eisai and Biogen have submitted a supplemental biologics license application to the FDA for monthly IV maintenance dosing of Leqembi to treat Alzheimer’s disease in patients with mild cognitive impairment or mild dementia.

More than half of patients with treatment-resistant depression achieved response with a single dose of BPL-003, a benzoate salt formulation of 5-MeO-DMT that is administered intranasally, according to a press release from the manufacturer.

The number one financial goal for most physicians is getting to a comfortable retirement on their own timeline and with the lifestyle they want.

Psychological distress about a cancer diagnosis may be associated with patients deliberately delaying the start of treatment, according to study findings.

The FDA has granted clearance to a transcranial magnetic stimulation device as an adjunctive treatment for major depressive disorder in patients aged 15 to 21 years, according to the manufacturer.

ChatGPT produced high-quality and accurate summaries of medical abstracts but struggled to classify the relevance of abstracts to medical specialties, a study published in the Annals of Family Medicine showed.

Russia’s 2022 invasion of Ukraine caused PTSD and worsened the mental health of adolescents and teens in the region, according to two studies.

Body dysmorphic disorder and appearance preoccupation were relatively common among youth, especially adolescent girls, according to a study published in Journal of the American Academy of Child & Adolescent Psychiatry.

A systematic review of hundreds of studies showed that medication has the best chance to improve ADHD outcomes in children and that other treatments have varied effects, according to results published in Pediatrics.

IGC Pharma has announced positive interim results from an ongoing phase 2 trial investigating IGC-AD1, a natural THC-based oral formulation, as a treatment for agitation in dementia from Alzheimer’s disease.